A simple facial photograph may reveal more than appearance. This study shows how tracking subtle changes in facial aging over time could help predict survival and reshape cancer care. Study: Face aging rate quantifies change in biological age to predict cancer outcomes. Image credit: hedgehog94/Shutterstock.com A study published in Nature Communications examines the predictive capability of photograph-based face aging rate (FAR) for overall survival in cancer patients. AI-derived facial age as a measurable biological indicator Biological aging rates vary substantially between individuals and can influence cancer outcomes independently of chronological age. However, their clinical use remains limited by the lack of practical, noninvasive biomarkers that can be easily applied in routine care. FaceAge is an artificial intelligence–based tool that estimates biological age from facial features such as skin texture, volume loss, and structural changes. Previous studies have shown that cancer patients predicted to be older than their chronological age have poorer survival outcomes, supporting its potential as a prognostic biomarker. Using Face Age to measure aging rate The authors previously developed a model called Foundation Artificial Intelligence Models for Health Recognition (FAHR-FaceAge), which was trained to recognize signs of ill-health on over 40 million facial images. When used with Face Age, they found that patients whose predicted age was five or more years greater than their chronological age had a 21 % higher mortality risk. Building on this, the researchers examined serial photographs to understand the signs associated with disease progression or treatment response. Such longitudinal measures are already widely used in clinical practice; for example, changes in prostate-specific antigen (PSA) levels over time help assess prostate cancer risk, while variability in blood pressure provides insight into cardiovascular risk. FAR and overall survival in cancer The researchers conducted a retrospective study on 2,276 cancer patients on radiation therapy. Most participants